The partnership allows Pathway to be the frontrunner in pharmacy partnerships for co-branded medical cannabis programs with a portfolio of formulations that are powered by the multi-patented VESIsorb® drug delivery system for optimal bioavailability and maximum therapeutic benefits.
Michael Davidson, M.D., has joined the company as Head of Innovation, Technology, and Clinical Research. He will leverage his successful track record in both pharmaceutical and nutritional clinical trials, and focus on first-to-market research that validates our science-backed product portfolio.
The company is leveraging a peer-reviewed, published CBD study and new product safety data from Geocann to build momentum after successful product launches in the U.S. The first large-scale production was completed and delivered earlier this month using only European resources.
Kanha Nano is available in a variety of delicious flavors and is currently sold in hundreds of retailers across California. According to Cameron Clarke, CEO of Sunderstorm, consumers have responded overwhelmingly positive with this product launch and report feeling the onset within minutes.
The specifics of the agreement are confidential and include a combination of cash, equity, and royalty payments to Geocann in exchange for the distribution rights of select VESIsorb® formulated CBD and CBG products to CVS, Walgreens, Rite-Aid, Kroeger, Walmart and Costco.
Science-backed ingredients – curcumin, cannabidiol (CBD), beta-caryophyllene (BCP), and vitamin D3 – have been successfully formulated with an innovative drug delivery technology in a softgel capsule for optimized absorption, bioavailability and therapeutic benefits.
The peer-reviewed journal, Molecules, has published the results of a double-blind, cross-over study confirming the superior results (Cmax, AUC, Tmax) of broad spectrum hemp oil formulated with VESIsorb® compared to the same broad spectrum hemp oil combined with medium chain triglyceride (MCT) oil.
CBG is among the many emerging cannabinoids and terpenes that Geocann is committed to pioneering through its technical formulation expertise and global distribution infrastructure. These product launches further advance Geocann’s leadership position as product development specialists.
The prestigious group is comprised of a multidisciplinary collective with decades of well-documented and published work as well as prominent careers focused on advancing the therapeutic benefits of science-backed natural ingredients, like cannabinoids and terpenes.
Industry-leading solution provider addresses the need to formulate cannabinoids with fast-acting and predictable onset, offering leading brands the ability to deliver the safest and most efficacious food and beverage products to cannabis consumers.
Atrium Innovations, a Nestlé Health Science company, expands product portfolio with patent-protected cannabinoid formulations utilizing the patented VESIsorb® drug delivery system. The products are marketed under Pure Encapsulations®, Douglas Laboratories® and Genestra Brands®.
Anthony Petraglia, M.D., joins Geocann as Chief Medical Officer to focus on the advancement of new product innovations that target the most pressing consumer health concerns as well as the research and publication of the company’s patent-protected portfolio of cannabis products.
The importance of stability data is often underestimated, especially in an emerging category like CBD where recent reports by the Food and Drug Administration (FDA), Consumer Lab, and many others, have shown that the majority of CBD products are falling short of their labeled claims.
Geocann has successfully commercialized the first formulation in a portfolio of CBD soft gel products that utilize the multi-patented VESIsorb® delivery system for optimal absorption and measured bioavailability. The formulation is loaded with a two-to-one ratio of CBD to BCP (beta-caryophyllene).
Geocann has successfully leveraged a robust intellectual property portfolio by applying patented drug delivery system technologies to cannabinoid formulations that are distributed to the global marketplace through strategic partnerships with category-dominant brands.
The pharmacokinetic performance of VESIsorb® is consistent and predictable. Pharmacological approaches to predicting efficacy traditionally start with measuring dissolution. It is widely accepted in the pharmaceutical industry that high dissolution correlates to optimal absorption of oral dosages.
Dr. Scott Martin hasn’t written a prescription in more than a year, although there was a time when he’d lecture on behalf of pharmaceutical companies. Now, Martin promotes hemp-based painkillers that would be covered by insurance as a cost-effective alternative before opioids are even considered.
"About 15 minutes and halfway into my smoothie, I was already beginning to feel the CBD's calming effects. For anyone unfamiliar with the benefits of the natural and legal cannabinoid, it's especially great for combating symptoms of anxiety." Nicole Yi, Pop Sugar
Reported by Pop Sugar: "Turmeric has been used for centuries as a natural anti-inflammatory that can outshine familiar drugs like ibuprofen. So what happens when you combine the powers of this spicy, muscle-healing root with fellow powerful anti-inflammatory CBD? A whole lot of awesome, that's what.
WillPower Product's ReGenPCR Powder and Sagely Naturals Relief and Recovery Capsules have been highlighted by Shape Magazine as two of the best "need to know" CBD products on the market for healthy-eating enthusiasts and hard-core gym-goers.
"Before I started this worldwide, in-depth investigation, I was not particularly impressed by the results of medical marijuana research, but a few years later, as I started to dedicate time with patients and scientists in various countries, I came to a different conclusion." Dr. Sanjay Gupta
Orchid Essentials is the first company to deliver a precise and consistent solid dosage form of Cannabidiol (CBD) formulated in a patented drug delivery system with measured and proven stability data to dispensaries throughout California.
TruEase® is the first soft gel containing CBD with measured and proven stability data ensuring the consumer receives the same levels of active ingredients from the first day of production to the last day of the promised shelf life.
Resaerch shows that 75% of supplement users said they would pay 10% or more extra for vitamins and supplements that were better absorbed. Nearly 60% of non supplement user said they would be wiling to pay more for supplements that are better absorbed.